JP2020532556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532556A5 JP2020532556A5 JP2020512822A JP2020512822A JP2020532556A5 JP 2020532556 A5 JP2020532556 A5 JP 2020532556A5 JP 2020512822 A JP2020512822 A JP 2020512822A JP 2020512822 A JP2020512822 A JP 2020512822A JP 2020532556 A5 JP2020532556 A5 JP 2020532556A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- ezh2
- ezh2 inhibitor
- agents
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 55
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 28
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 28
- 239000003814 drug Substances 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 7
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 4
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 4
- 108091007960 PI3Ks Proteins 0.000 claims 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 4
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 4
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 4
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 4
- 239000002168 alkylating agent Substances 0.000 claims 4
- 229940100198 alkylating agent Drugs 0.000 claims 4
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical group C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims 4
- 229950004774 tazemetostat Drugs 0.000 claims 4
- 102000043136 MAP kinase family Human genes 0.000 claims 3
- 108091054455 MAP kinase family Proteins 0.000 claims 3
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims 2
- 229940125431 BRAF inhibitor Drugs 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 102000016397 Methyltransferase Human genes 0.000 claims 2
- 229940121878 P300 inhibitor Drugs 0.000 claims 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 claims 2
- 101150040313 Wee1 gene Proteins 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 claims 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108050009309 Tuberin Proteins 0.000 claims 1
- 102000044633 Tuberous Sclerosis Complex 2 Human genes 0.000 claims 1
- 229940122530 Tubulin polymerization inhibitor Drugs 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229950001573 abemaciclib Drugs 0.000 claims 1
- 229960001686 afatinib Drugs 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 229950004272 brigatinib Drugs 0.000 claims 1
- 229950003628 buparlisib Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960001602 ceritinib Drugs 0.000 claims 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960005061 crizotinib Drugs 0.000 claims 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims 1
- 229960003278 osimertinib Drugs 0.000 claims 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960004390 palbociclib Drugs 0.000 claims 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 229950003687 ribociclib Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960004066 trametinib Drugs 0.000 claims 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 1
- SZCZSKMCTGEJKI-UHFFFAOYSA-N tuberin Natural products COC1=CC=C(C=CNC=O)C=C1 SZCZSKMCTGEJKI-UHFFFAOYSA-N 0.000 claims 1
- 229950011257 veliparib Drugs 0.000 claims 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023174378A JP2024001203A (ja) | 2017-09-05 | 2023-10-06 | 癌を処置するための併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762554484P | 2017-09-05 | 2017-09-05 | |
| US62/554,484 | 2017-09-05 | ||
| PCT/US2018/049516 WO2019050924A1 (en) | 2017-09-05 | 2018-09-05 | POLY THERAPY FOR THE TREATMENT OF CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174378A Division JP2024001203A (ja) | 2017-09-05 | 2023-10-06 | 癌を処置するための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532556A JP2020532556A (ja) | 2020-11-12 |
| JP2020532556A5 true JP2020532556A5 (enExample) | 2021-10-14 |
| JP7399079B2 JP7399079B2 (ja) | 2023-12-15 |
Family
ID=65635164
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512822A Active JP7399079B2 (ja) | 2017-09-05 | 2018-09-05 | 癌を処置するための併用療法 |
| JP2023174378A Withdrawn JP2024001203A (ja) | 2017-09-05 | 2023-10-06 | 癌を処置するための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174378A Withdrawn JP2024001203A (ja) | 2017-09-05 | 2023-10-06 | 癌を処置するための併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11452727B2 (enExample) |
| EP (1) | EP3678663A4 (enExample) |
| JP (2) | JP7399079B2 (enExample) |
| CN (1) | CN111093660A (enExample) |
| CA (1) | CA3074720A1 (enExample) |
| WO (1) | WO2019050924A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| BR112015008447A2 (pt) | 2012-10-15 | 2017-07-04 | Epizyme Inc | métodos para tratar câncer |
| CA3074720A1 (en) * | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN111217802B (zh) * | 2018-11-27 | 2021-10-08 | 海创药业股份有限公司 | 一类组蛋白乙酰化酶p300抑制剂及其用途 |
| WO2021035168A1 (en) * | 2019-08-22 | 2021-02-25 | Thomas Jefferson University | Methods for reprogramming cancer cells |
| TW202114670A (zh) * | 2019-09-30 | 2021-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 一種ezh2抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤藥物中的用途 |
| CN112870366B (zh) * | 2019-11-29 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂在制备治疗肿瘤药物中的新用途 |
| CN112870367B (zh) * | 2019-11-29 | 2023-01-20 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂、cdk4/6抑制剂和mek抑制剂在制备治疗肿瘤药物中的用途 |
| MX2023012294A (es) * | 2021-04-21 | 2023-10-26 | Celgene Corp | Metodos de tratamiento del linfoma no hodgkin mediante el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il) metil)benzil)amino)isoindolin-1,3-diona. |
| US20240335452A1 (en) * | 2021-08-04 | 2024-10-10 | Cullgen (Shanghai), Inc. | Compositions and methods of combination therapy for targeting lymphoma |
| EP4151208A1 (en) * | 2021-09-17 | 2023-03-22 | Universite De Bordeaux | Novel synergistic combinations and methods of uses thereof for treating cancers |
| WO2024059696A1 (en) * | 2022-09-15 | 2024-03-21 | Recurium Ip Holdings, Llc | Combinations |
| CN116099005B (zh) * | 2023-03-16 | 2025-02-07 | 嘉兴大学 | GSK126通过增加维甲酸受体γ基因表达增强肝癌细胞对全反式维甲酸的反应 |
| WO2025166537A1 (en) * | 2024-02-06 | 2025-08-14 | Epizyme, Inc. | Methods of treatment using an ezh2 modulator |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6389036B2 (ja) | 2010-09-10 | 2018-09-12 | エピザイム インコーポレイテッド | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| CA2867282C (en) | 2012-03-12 | 2024-04-02 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| RU2699546C2 (ru) | 2012-04-13 | 2019-09-06 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
| PL3184523T3 (pl) | 2012-04-13 | 2019-12-31 | Epizyme Inc | Bromowodorek N-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5- (etylo(tetrahydro-2H-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'- bifenylo]-3-karboksyamidu do zastosowania w leczeniu zaburzenia proliferacji komórkowej układu hematologicznego |
| BR112015008447A2 (pt) | 2012-10-15 | 2017-07-04 | Epizyme Inc | métodos para tratar câncer |
| SG10201705989YA (en) | 2012-10-15 | 2017-08-30 | Epizyme Inc | Substituted benzene compounds |
| EP2935214B1 (en) | 2012-12-21 | 2019-02-20 | Epizyme, Inc. | 1,4-pyridone compounds |
| WO2014100665A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| HK1220916A1 (zh) | 2013-03-14 | 2017-05-19 | 基因泰克公司 | 治疗癌症和预防癌症药物抗性的方法 |
| WO2014144747A1 (en) | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| CA2903572A1 (en) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
| US10150764B2 (en) | 2013-07-19 | 2018-12-11 | Epizyme, Inc. | Substituted benzene compounds |
| US9624205B2 (en) | 2013-07-19 | 2017-04-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| EP4324525A3 (en) | 2013-10-16 | 2024-07-17 | Epizyme, Inc. | Hydrochloride salt form for ezh2 inhibition |
| US20160228447A1 (en) | 2013-10-18 | 2016-08-11 | Epizyme, Inc. | Method of treating cancer |
| WO2015085325A1 (en) | 2013-12-06 | 2015-06-11 | Epizyme, Inc. | Combination therapy for treating cancer |
| KR20230031963A (ko) | 2014-06-17 | 2023-03-07 | 에피자임, 인코포레이티드 | 림프종 치료를 위한 ｅｚｈ2 억제제 |
| WO2015200650A1 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| US20160235716A1 (en) | 2014-09-18 | 2016-08-18 | Abbvie Inc. | Spirocyclic hat inhibitors and methods for their use |
| CN106794177A (zh) | 2014-10-16 | 2017-05-31 | Epizyme股份有限公司 | 治疗癌症的方法 |
| KR20240035908A (ko) | 2014-11-17 | 2024-03-18 | 에피자임, 인코포레이티드 | 암을 치료하기 위한 방법 |
| TW201713327A (zh) * | 2015-04-17 | 2017-04-16 | 波士頓生醫公司 | 治療癌症之方法 |
| WO2016172199A1 (en) * | 2015-04-20 | 2016-10-27 | Epizyme, Inc. | Combination therapy for treating cancer |
| CA2988816A1 (en) | 2015-06-10 | 2016-12-15 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
| US10493076B2 (en) | 2015-08-24 | 2019-12-03 | Epizyme, Inc. | Method for treating cancer |
| CN108349958B (zh) | 2015-09-25 | 2022-02-15 | Epizyme股份有限公司 | 用ezh2抑制剂治疗mrto/sccoht的方法 |
| EP4309738A3 (en) | 2015-10-06 | 2024-07-17 | Epizyme, Inc. | Method of treating medulloblastoma with an ezh2 inhibitor |
| EP3370725A4 (en) | 2015-11-06 | 2019-07-03 | Epizyme, Inc. | PEDIATRIC DOSAGE FOR THE TREATMENT OF CANCER WITH AN EZH2 INHIBITOR |
| CN108368553A (zh) | 2015-11-20 | 2018-08-03 | 斯特拉斯堡大学 | 确定癌症患者的个性化治疗策略的方法 |
| JP2018536009A (ja) | 2015-12-07 | 2018-12-06 | エピザイム，インコーポレイティド | Ｅｚｈ２の阻害剤およびその使用の方法 |
| WO2017106556A1 (en) * | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
| US11951108B2 (en) | 2016-01-29 | 2024-04-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2017139404A1 (en) * | 2016-02-08 | 2017-08-17 | Epizyme, Inc. | Methods of treating cancer |
| JP7121660B2 (ja) * | 2016-06-01 | 2022-08-18 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| MA45406A (fr) | 2016-06-17 | 2019-04-24 | Epizyme Inc | Inhibiteurs d'ezh2 pour traiter le cancer |
| AU2017367768A1 (en) | 2016-12-02 | 2019-07-18 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018217139A1 (en) | 2017-02-02 | 2019-08-22 | Epizyme, Inc. | Cancer treatment modalities |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| CA3060416A1 (en) * | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| JP2020522687A (ja) * | 2017-06-02 | 2020-07-30 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| WO2018231973A1 (en) | 2017-06-13 | 2018-12-20 | Epizyme, Inc. | Inhibitors of ezh2 and methods of use thereof |
| CA3074720A1 (en) * | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| IL295654A (en) * | 2020-02-19 | 2022-10-01 | Epizyme Inc | Setd2 inhibitors and related methods and uses, including combination therapies |
-
2018
- 2018-09-05 CA CA3074720A patent/CA3074720A1/en active Pending
- 2018-09-05 CN CN201880057161.0A patent/CN111093660A/zh active Pending
- 2018-09-05 US US16/644,202 patent/US11452727B2/en active Active
- 2018-09-05 WO PCT/US2018/049516 patent/WO2019050924A1/en not_active Ceased
- 2018-09-05 JP JP2020512822A patent/JP7399079B2/ja active Active
- 2018-09-05 EP EP18853157.8A patent/EP3678663A4/en not_active Withdrawn
-
2022
- 2022-08-22 US US17/892,651 patent/US20230000877A1/en not_active Abandoned
-
2023
- 2023-10-06 JP JP2023174378A patent/JP2024001203A/ja not_active Withdrawn
-
2024
- 2024-02-02 US US18/431,262 patent/US20240277721A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532556A5 (enExample) | ||
| JP2020504742A5 (enExample) | ||
| JP6063628B2 (ja) | ５−アザシチジンを用いる、非小細胞肺癌の治療方法 | |
| JP2016519684A (ja) | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 | |
| KR20190011770A (ko) | 암 치료 | |
| CN103282037A (zh) | 抗肿瘤生物碱的联合治疗 | |
| WO2017200016A1 (ja) | Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬 | |
| WO2023035611A1 (en) | Pharmaceutical composition and use thereof | |
| CN112236147A (zh) | 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物和其使用方法 | |
| ES2361550T3 (es) | Combinación de la roscovitina y de cs-682 o de su metabolito cndac. | |
| EP2726076B1 (en) | Combination therapy | |
| RU2008138534A (ru) | Фармацевтическая комбинация для лечения и/или хемосенсебилизации опухолей, устойчивых к противораковым средствам | |
| Luo et al. | Discovery and optimization of selective RET inhibitors via scaffold hopping | |
| De Paoli et al. | Neoadjuvant therapy of rectal cancer new treatment perspectives | |
| AR049136A1 (es) | Composicion y metodo con irinotecan (cpt-11) y un inhibidor del egfr,como erlotinib | |
| Okuma et al. | S-1 is an active anticancer agent for advanced thymic carcinoma | |
| JP2007513967A5 (enExample) | ||
| US10765675B2 (en) | Compositions and methods for treating Ewing family tumors | |
| JPWO2021182571A5 (enExample) | ||
| KR20070030240A (ko) | 암 치료 방법 | |
| US20050276866A1 (en) | Combination comprising a CDK inhibitor and cisplatin | |
| RU2519199C2 (ru) | Противоопухолевый агент, набор и способ лечения рака | |
| JP6581308B2 (ja) | 癌治療剤 | |
| Peters et al. | EORTC-related new drug discovery and development activities: Role of the Pharmacology and Molecular Mechanisms Group | |
| WO2022171064A1 (zh) | 烟酰胺及含有其的组合物的制药用途 |